DESCRIPTION
id: 258d66ff-6f9c-40f8-8b52-c42c60e22ed4
displayName: DESCRIPTION SECTION
FDA Article Code: 34089-3
Doxycycline hyclate is available as a 20 mg tablet formulation of doxycycline for oral administration.
The structural formula of doxycycline hyclate is:
with an emperical formula of (C22H24N2O8•HCl)2•C2H6O•H2O and a molecular weight of 1025.89. The chemical designation for doxycycline is 4-(dimethylamino)-1, 4, 4a, 5, 5a, 6, 11, 12a-octahydro-3, 5, 10, 12, 12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride, compound with ethyl alcohol (2:1), monohydrate.
Doxycycline hyclate is a yellow to light-yellow crystalline powder which is soluble in water.
Each tablet for oral administration contains 23 mg doxycycline hyclate equivalent to 20 mg of doxycycline. In addition, each tablet contains the following inactive ingredients: anhydrous lactose, carnauba wax, croscarmellose sodium, hypromellose, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, titanium dioxide, and triacetin.
CLINICAL PHARMACOLOGY
id: c94a5012-365e-4227-b995-fa8293a3fc57
displayName: CLINICAL PHARMACOLOGY SECTION
FDA Article Code: 34090-1
After oral administration, doxycycline hyclate is rapidly and nearly completely absorbed from the gastrointestinal tract. Doxycycline is eliminated with a half-life of approximately 18 hours by renal and fecal excretion of unchanged drug.
INDICATIONS AND USAGE
id: 554b81fc-80a5-4a99-9efe-75bb3af85e7c
displayName: INDICATIONS & USAGE SECTION
FDA Article Code: 34067-9
Doxycycline hyclate is indicated for use as an adjunct to scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with adult periodontitis.
CONTRAINDICATIONS
id: 7a9c56ef-c724-49d8-9b5e-c58dfa7ed183
displayName: CONTRAINDICATIONS SECTION
FDA Article Code: 34070-3
This drug is contraindicated in persons who have shown hypersensitivity to doxycycline or any of the other tetracyclines.
WARNINGS
id: ee763d1d-6321-465c-8f14-20f6715d42bf
displayName: WARNINGS SECTION
FDA Article Code: 34071-1
THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY AND CHILDHOOD TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW-GRAY-BROWN). This adverse reaction is more common during long-term use of the drugs but has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED IN THIS AGE GROUP AND IN PREGNANT OR NURSING MOTHERS UNLESS THE POTENTIAL BENEFITS MAY BE ACCEPTABLE DESPITE THE POTENTIAL RISKS.
All tetracyclines form a stable calcium complex in any bone forming tissue. A decrease in fibula growth rate has been observed in premature infants given oral tetracyclines in doses of 25 mg/kg every 6 hours. This reaction was shown to be reversible when the drug was discontinued.
Doxycycline can cause fetal harm when administered to a pregnant woman. Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity has also been noted in animals treated early in pregnancy. If any tetracyclines are used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
The catabolic action of the tetracyclines may cause an increase in BUN. Previous studies have not observed an increase in BUN with the use of doxycycline in patients with impaired renal function.
Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.
PRECAUTIONS
id: ab9752cd-e996-4f20-b622-e71ccba7f365
displayName: PRECAUTIONS SECTION
FDA Article Code: 42232-9
While no overgrowth by opportunistic microorganisms such as yeast were noted during clinical studies, as with other antimicrobials, doxycycline hyclate therapy may result in overgrowth of nonsusceptible microorganisms including fungi.
The use of tetracyclines may increase the incidence of vaginal candidiasis.
Doxycycline hyclate should be used with caution in patients with a history or predisposition to oral candidiasis. The safety and effectiveness of doxycycline hyclate has not been established for the treatment of periodontitis in patients with coexistant oral candidiasis.
If superinfection is suspected, appropriate measures should be taken.
OVERDOSAGE
id: 000b5494-d0ae-4d48-bcdd-c8ee6d6d3e92
displayName: OVERDOSAGE SECTION
FDA Article Code: 34088-5
In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Dialysis does not alter serum half-life and thus would not be of benefit in treating cases of overdose.
DOSAGE AND ADMINISTRATION
id: 24a5e089-d78f-44f5-a4bb-cccafb6eeeab
displayName: DOSAGE & ADMINISTRATION SECTION
FDA Article Code: 34068-7
THE DOSAGE OF DOXYCYCLINE HYCLATE TABLETS DIFFERS FROM THAT OF DOXYCYCLINE USED TO TREAT INFECTIONS. EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS INCLUDING THE DEVELOPMENT OF RESISTANT MICROORGANISMS.
Doxycycline hyclate tablets 20 mg twice daily as an adjunct following scaling and root planing may be administered for up to 9 months. Doxycycline hyclate tablets should be taken twice daily at 12 hour intervals, usually in the morning and evening. It is recommended that if doxycycline hyclate tablets are taken close to meal times, allow at least one hour prior to or two hours after meals. Safety beyond 12 months and efficacy beyond 9 months have not been established.
Administration of adequate amounts of fluid along with the tablets is recommended to wash down the drug and reduce the risk of esophageal irritation and ulceration. (See
ADVERSE REACTIONS
Section).
HOW SUPPLIED
id: 52d55ced-f002-4809-9373-20217616f52f
displayName: HOW SUPPLIED SECTION
FDA Article Code: 34069-5
Doxycycline hyclate tablets USP equivalent to 20 mg of doxycycline, round, white, unscored, film coated tablet, debossed MP 573 on one side and blank on the other side.
| Bottles of 10 |
NDC 54868-5269-1
|
| Bottles of 60
|
NDC 54868-5269-0
|
REFERENCES
id: aa3d83d1-9315-4130-b6d0-583a4c9869b7
displayName: REFERENCES SECTION
FDA Article Code: 34093-5
- Golub L.M., Sorsa T., Lee H-M, Ciancio S., Sorbi D., Ramamurthy N.S., Gruber B., Salo T., Konttinen Y.T.: Doxycycline Inhibits Neutrophil (PMN)-type Matrix Metalloproteinases in Human Adult Periodontitis Gingiva. J. Clin. Periodontol 1995; 22: 100–109.
- Golub L.M., Ciancio S., Ramamurthy N.S., Leung M., McNamara T.F.: Low-dose Doxycycline Therapy: Effect on Gingival and Crevicular Fluid Collagenase Activity in Humans. J. Periodont Res 1990; 25: 321–330.
- Golub L.M., Lee H.M., Greenwald R.A., Ryan M.E., Salo T., Giannobile W.V.: A Matrix Metalloproteinase Inhibitor Reduces Bone-type Collagen Degradation Fragments and Specific Collegenases in Gingival Crevicular Fluid During Adult Periodontitis. Inflammation Research 1997; 46: 310–319.
- Saivain S., Houin G.: Clinical Pharmacokinetics of Doxycycline and Minocycline. Clin. Pharmacokinetics 1988; 15: 355–366.
- Schach von Wittenau M., Twomey T.: The Disposition of Doxycycline by Man and Dog. Chemotherapy 1971; 16: 217–228.
- Campistron G., Coulais Y., Caillard C., Mosser J., Pontagnier H., Houin G.: Pharmacokinetics and Bioavailability of Doxycycline in Humans. Arzneimittel Forschung 1986; 36: 1705–1707.
PRINCIPAL DISPLAY PANEL
id: bc8d637e-5ffc-4c27-8ddc-ef012ff77848
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4
NDC 54868-5269-0
DOXYCYCLINE HYCLATE
TABLETS USP
20 mg
Rx only
